DENND2C

Across TCGA pan-cancer cohorts, DENND2C Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated DENND2C data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DENND2C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DENND2C expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, UCS, and UCEC are the cancer types where DENND2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.031	0.779	<.001	48	view →
UCS	OS	Median	All	0.001	0.690	<.001	36	view →
UCEC	DFS	Median	All	0.975	0.612	.001	32	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	18	view →
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
LUAD	OS	Median	III,IV	0.068	0.680	<.001	12	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
COAD	OS	Median	All	0.248	0.701	.002	12	view →
SKCM	OS	Median	III,IV	0.936	0.684	.023	7	view →
SARC	OS	Median	All	0.241	0.766	.022	6	view →
LGG	DFS	Median	All	0.249	0.728	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

DENND2C–LIHC (OS)

Open the LIHC breakdown →